CREB3 and osteosarcoma: In patients with osteosarcoma, circTada2a was reported to promote the development of osteosarcoma and increase tumor malignant behavior through miR-203a-3p/CREB3 axis, which was expected to be a new therapeutic target for osteosarcoma [19].